MetaCap

Alumis (ALMS) vs Wave Life Sciences (WVE)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Alumis (ALMS) has outperformed Wave Life Sciences (WVE) over the past year, losing 45.8% versus a loss of 63.7%. Alumis is the larger company by market cap ($514.1 million vs $504.9 million), about 1.0 times the size. Wave Life Sciences converts more of its revenue into profit, with a net margin of -478.3% versus -1011.7%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ALMS-45.75%WVE-63.69%
+334%+126%-83%
Nov 21, 20251 yearNov 20, 2026
ALMS-70.23%WVE-48.70%
+273%+89%-95%
Jun 24, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ALMS versus WVE key metrics
MetricALMSWVE
Share price$3.96$2.56
Market cap$514.09M$504.91M
1-day change-8.55%-5.88%
YTD return-59.43%-84.94%
1-year return-45.75%-63.69%
5-year return—-35.84%
EPS (TTM)$-3.53$-1.07
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$24.05M$42.73M
Revenue growth (YoY)—-60.55%
Net income (latest FY)$-243.32M$-204.38M
Operating margin-1886.92%-504.09%
Net margin-1011.75%-478.33%
52-week high$31.35$21.73
52-week low$3.94$2.55
Distance from 52-week high-87.37%-88.22%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+540.91%+549.61%
Average volume2.87M3.11M
Shares outstanding129.82M197.23M
Employees251317
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ALMS has outperformed WVE by 17.9 percentage points over the past year.
  • Wave Life Sciences is more profitable, keeping -478.3 cents of every revenue dollar as net income versus -1011.7 cents for Alumis.

About Alumis

ALMS stock →

Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 251 employees

About Wave Life Sciences

WVE stock →

Wave Life Sciences, Inc., a clinical-stage biotechnology company, focuses on unlocking the potential of ribonucleic acid (RNA) medicines to transform human health. Its RNA medicines platform, PRISM, combines RNA medicine modalities, chemistry innovation, and deep insights in human genetics to deliver scientific breakthroughs that treat rare and common disorders.

Health Care · Biotechnology: Pharmaceutical Preparations · 317 employees

ALMS vs WVE FAQ

Which is bigger, Alumis or Wave Life Sciences?

Alumis (ALMS) is larger, with a market capitalization of $514.09M compared with $504.91M for Wave Life Sciences (WVE).

Which stock has performed better over the past year, ALMS or WVE?

ALMS returned -45.75% over the past 12 months, compared with -63.69% for WVE (price return, excluding dividends). Past performance does not predict future results.

Are Alumis and Wave Life Sciences in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons